Biovail Corporation (NYSE: BVF) (TSX: BVF) announced that it has received Approval from the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for Aplenzin™ (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults.
Popularity: 1% [?]
Related posts:
- Aplenzin(TM), The Only Single Tablet Once-Daily Treatment For Depression At All Doses, Now Available In The United States
- Biovail Receives Canadian Approval For Wellbutrin(R) XL For The Prevention Of Seasonal Major Depressive Illness
- Actavis Receives Approval Of Generic Wellbutrin XL(R) 300mg In The United States
- Labopharm Receives Complete Response Letter From The U.S. FDA For Novel Antidepressant
- Par Pharmaceutical Receives Final Approval To Market Tranylcypromine Sulfate Tablets
Comments
No Responses to “Biovail Receives FDA Approval For Aplenzin (BVF-033) For The Treatment Of Depression”